The group compared the efficacy of IL-2 fusion toxin with developed anti-human CCR4 immunotoxin (CCR4 IT) and demonstrated that CCR4 IT showed greater tumor response in a CD25 + CCR4 + CTCL mouse model than IL-2 fusion toxin. Here, CCR4 is linked to neoplasm.